Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 2.0 | 5.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 1.56 | 1.37 |
NAV | ₹114.27 | ₹197.07 |
Fund Started | 31 Jan 2011 | 07 May 2007 |
Fund Size | ₹31146.94 Cr | ₹84854.73 Cr |
Exit Load | Exit Load for units in excess of 10% of the investment,1% will be charged for redemption within 12 months. | Exit load of 1% if redeemed within 1 year. |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | -0.54% | 3.35% |
3 Year | 18.62% | 25.70% |
5 Year | 21.84% | 29.27% |
1 Year
3 Year
5 Year
Equity | 91.64% | 93.60% |
Cash | -0.01% | 6.40% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
---|---|
Fortis Healthcare Ltd. | 4.14% |
UNO Minda Ltd. | 2.68% |
JK Cement Ltd. | 2.51% |
The Indian Hotels Company Ltd. | 2.50% |
GE Vernova T&D India Ltd | 2.32% |
Bharti Hexacom Ltd. | 2.19% |
Dixon Technologies (India) Ltd. | 2.13% |
Schaeffler India Ltd. | 2.11% |
Coromandel International Ltd. | 2.06% |
The Federal Bank Ltd. | 1.99% |
Name | Assets |
---|---|
Max Financial Services Ltd. | 4.76% |
Balkrishna Industries Ltd. | 3.54% |
Indian Bank | 3.26% |
Fortis Healthcare Ltd. | 3.18% |
AU Small Finance Bank Ltd. | 3.16% |
Coforge Ltd. | 2.93% |
The Federal Bank Ltd. | 2.91% |
Hindustan Petroleum Corporation Ltd. | 2.90% |
Glenmark Pharmaceuticals Ltd. | 2.87% |
Ipca Laboratories Ltd. | 2.80% |
Name | Vinayak Jayanath | Chirag Setalvad |
Start Date | 12 Dec 2023 | 28 Jun 2014 |
Name
Start Date
Description | The scheme seeks to achieve long term capital appreciation by investing predominantly in equity & equity related instruments of Mid Cap companies. | The scheme seeks to provide long-term capital appreciation/income by investing predominantly in Mid-Cap companies. |
Launch Date | 31 Jan 2011 | 07 May 2007 |
Description
Launch Date